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Background: We aimed to investigate whether the presence or absence of structural alterations of the epicardial artery may affect the 
manifestation of the longitudinal, base-to-apex myocardial blood flow (MBF) gradient during pharmacologic vasodilation.
Methods: MBF was measured with N-13 ammonia and PET/CT in ml/g/min at rest and during dipyridamole stimulation in 15 healthy controls 
(CON), and in individuals with traditional cardiovascular risk factors but without CAC (group 1; n= 20) or with CAC (group 2; n=24). Non-invasive 
CT-coronary angiography (CTA) was performed with 64 slice CT of the PET/CT system and the coronary calcium score (CCS) was also determined. MBF 
was determined globally as mean MBF, and in the mid and mid-distal myocardial segment of the left ventricle (LV). A decrease of MBF from mid to 
mid-distal LV myocardium was defined as longitudinal MBF gradient.
Results: Compared with CON, the global hyperemic MBF progressively declined in group 1 and group 2 (2.31±0.62 vs. 1.66±0.40 and 1.47±0.38 
ml/g/min, respectively; p<0.001). CON and group 2 had no CCS and normal CTA, while in group 1 the mean CCS was 899±955 HU and no focal 
stenosis ≥ 50% diameter stenosis was identified on CTA. Absolute MBFs during dipyridamole stimulation were significantly lower in the mid-distal 
than in the mid LV myocardium in CON, group 1 and group 2 (2.26±0.60 vs. 2.30±0.60, 1.44±0.35 vs. 1.80±0.42, and 1.34±0.32 vs 1.58±0.38 
ml/g/min, p<0.0001), resulting in a MBF gradient that was highest in group1, intermediate in group 2 and lowest in CON (0.35±0.18 and 
0.23±0.09 vs. 0.12±0.03 ml/g/min, respectively, p<0.0001). Notably, the MBF gradient in group 1-2 was significantly associated with the mid LV 
MBF during hyperemic flows (r= 0.65, p<0.0001), implicating the flow velocity as important determinant of the MBF gradient. 
Conclusions: The longitudinal hyperemic MBF gradient was more pronounced in cardiovascular risk individuals without CAC than in those with 
CAC, while it depended on the velocity of the hyperemic flow increase. In the absence of structural CAD, a disturbance of flow-mediated epicardial 
vasodilation is likely to account for the longitudinal MBF gradient during hyperemic flows.
